drugset / Trial / NCT02502188
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of CC-90005 in healthy subjects and subjects with moderate to severe plaque-type psoriasis.
Timeline
- Start
- 2015-07-17
- Primary completion
- 2015-11-02
- Completion
- 2015-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CC-90005 | Unknown | — | Oral |